Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305312 | 0.92 | CYP19A1 (0.67) | HDAC1HDAC6CYP19A1STSS1PR1 | |
| SCHEMBL3639750 | 0.87 | HDAC1 (0.73) | HDAC1HDAC6CYP19A1HTTSTS | |
| SCHEMBL306427 | 0.85 | HDAC1 (0.70) | HDAC1HDAC6CYP19A1HTTSTS | |
| SCHEMBL7079785 | 0.83 | CYP19A1 (0.56) | HDAC1HDAC6CYP19A1MEN1KMT2A | |
| SCHEMBL4330785 | 0.81 | HDAC1 (0.49) | HDAC1HDAC6CYP19A1STSTDP1 | |
| SCHEMBL28303703 | 0.80 | HDAC1 (0.64) | HDAC1HDAC6CYP19A1HTTL3MBTL1 | |
| SCHEMBL5481318 | 0.80 | HDAC1 (0.60) | HDAC1HDAC6CYP19A1HTTSTS | |
| SCHEMBL14496524 | 0.79 | CYP19A1 (0.67) | HDAC1HDAC6CYP19A1STS | |
| SCHEMBL3460275 | 0.78 | HDAC1 (0.64) | HDAC1HDAC6CYP19A1STS | |
| SCHEMBL3754518 | 0.78 | HDAC1 (0.64) | HDAC1HDAC6CYP19A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | HDAC1 498/4885HDAC6 1059/4885CYP19A1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.